Drug Profile


Alternative Names: BMS-562247; BMS-562247-01; Eliquis

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Phase III Acute coronary syndromes

Most Recent Events

  • 01 Jan 2017 Phase-II clinical trials in Thromboembolism (In adolescents, In children, In infants, Prevention) in USA (PO, Tablet) (NCT02981472)
  • 01 Jan 2017 Phase-II clinical trials in Thromboembolism (In adolescents, In infants, In children, Prevention) in USA (PO, Liquid) (NCT02981472)
  • 18 Nov 2016 Bristol-Myers Squibb, Pfizer and Pediatric Heart Network plan a phase II trial for Thromboembolism (Prevention) in Argentina, Austria, Australia, Brazil, Canada, Finland, France, Germany, Israel, Italy, Mexico, Ireland, Netherlands, Spain, Sweden, United Kingdom and USA (NCT02981472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top